Patents Assigned to Genentech
  • Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
    Patent number: 7862817
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: January 4, 2011
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
  • METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES
    Publication number: 20100330096
    Abstract: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.
    Type: Application
    Filed: September 7, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventor: Kyung Jin Kim
  • POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
    Publication number: 20100331251
    Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
    Type: Application
    Filed: March 23, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Sophia S. Kuo
  • NLRR-1 ANTAGONISTS AND USES THEREOF
    Publication number: 20100330082
    Abstract: NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided.
    Type: Application
    Filed: October 1, 2008
    Publication date: December 30, 2010
    Applicant: GENENTECH INC.
    Inventors: Meredith Hazen, Jo-Anne S. Hongo, Victoria Smith, Susanna Stinson
  • OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20100331305
    Abstract: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
    Type: Application
    Filed: June 23, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventors: Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F.T. Koehler, Cuong Ly, Joseph P. Lyssikatos, Zhonghua Pei, Wendy Lee, Xianrui Zhao
  • PLASMINOGEN ACTIVATOR VARIANT FORMULATIONS
    Publication number: 20100330083
    Abstract: A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof, as well as in kits. In a preferred embodiment, peripheral thrombosis is treated in a mammal comprising delivering to the mammal via a catheter an effective amount of this solution.
    Type: Application
    Filed: June 23, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventor: Charles P. SEMBA
  • Compositions and methods for the treatment of tumor of hematopoietic origin
    Patent number: 7858330
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: December 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Jo-Anne Hongo, Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen D. Frantz, Hartmut Koeppen, Andrew Polson, Victoria Smith
  • Process for bacterial production of polypeptides
    Patent number: 7858339
    Abstract: Refractile particles containing a heterologous polypeptide as an insoluble aggregate are recovered from bacterial periplasm. The process involves culturing bacterial cells so as to express nucleic acid encoding phage lysozyme and nucleic acid encoding the heterologous polypeptide under separate promoters, disrupting the cells mechanically to release the phage lysozyme so as to release refractile particles from the bacterial cellular matrix, and recovering the released refractile particles from the periplasm. Chloroform is not used in any step and the recovery step minimizes co-recovery of cellular debris with the released refractile particles.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: December 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Woon-Lam Susan Leung, James R. Swartz
  • Gene disruptions, compositions and methods relating thereto
    Patent number: 7858843
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: December 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Ling Ling Culbertson, Frederic J. de Sauvage, Charles Montgomery, Zheng-Zheng Shi, Mary Jean Sparks
  • MULTISPECIFIC ANTIBODIES
    Publication number: 20100322946
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Application
    Filed: September 1, 2009
    Publication date: December 23, 2010
    Applicant: Genentech, Inc.
    Inventors: Jenny M. Bostrom, Germaine Fuh
  • Cysteine engineered antibodies and conjugates
    Patent number: 7855275
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
  • Methods for making Apo-2 ligand using divalent metal ions
    Patent number: 7855066
    Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.
    Type: Grant
    Filed: September 28, 2006
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
  • Aza-indolyl compounds and methods of use
    Patent number: 7855216
    Abstract: The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Karen Williams, Stephen Price, Hazel Joan Dyke, John Gary Montana, Mark S. Stanley, Liang Bao, Wendy Lee
  • Antibodies to Stra6 polypeptides
    Patent number: 7855278
    Abstract: The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Diane Pennica, Victoria Smith, William I. Wood
  • BIOMARKERS FOR IGF-1R INHIBITOR THERAPY
    Publication number: 20100316639
    Abstract: The invention concerns the identification and validation of certain biomarkers for selecting patients for therapy with an IGF-1R inhibitor, particularly for breast and colorectal cancer.
    Type: Application
    Filed: June 15, 2010
    Publication date: December 16, 2010
    Applicant: Genentech, Inc.
    Inventor: MARK R. LACKNER
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS
    Publication number: 20100316652
    Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.
    Type: Application
    Filed: August 23, 2010
    Publication date: December 16, 2010
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kyung Jin Kim
  • INHIBITION OF ANGIOGENESIS
    Publication number: 20100316633
    Abstract: The present invention relates generally to the inhibition of inflammatory cell-mediated angiogenesis. In particular, the invention concerns the prevention or treatment of tumor angiogenesis, and the inhibition of tumor development, using Bv8 antagonists, such as anti-Bv8 antibodies.
    Type: Application
    Filed: September 19, 2008
    Publication date: December 16, 2010
    Applicant: Genentech, Inc.
    Inventors: Napoleon Ferrara, Fabod Shojaei, Xiumin Wu, Cuiling Zhong
  • JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20100317643
    Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof
    Type: Application
    Filed: June 10, 2010
    Publication date: December 16, 2010
    Applicant: GENENTECH, INC.
    Inventors: SIMON CHARLES GOODACRE, YINGJIE LAI, JUN LIANG, STEVEN R. MAGNUSON, KIRK D. ROBARGE, MARK S. STANLEY, VICKIE HSIAO-WEI TSUI, KAREN WILLIAMS, BIRONG ZHANG, AIHE ZHOU
  • Method of treating breast cancer using anti-HER2 antibody variants
    Patent number: 7850966
    Abstract: The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: December 14, 2010
    Assignee: Genentech, Inc.
    Inventors: Henry B. Lowman, Resi B. Gerstner, Paul J. Carter
  • Treatment with anti-ErbB2 antibodies
    Patent number: 7846441
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: December 7, 2010
    Assignee: Genentech, Inc.
    Inventor: Susan D. Hellmann